Literature DB >> 6661688

Responses to ligation of a coronary artery in conscious rats and the actions of antiarrhythmics.

K M Johnston, B A MacLeod, M J Walker.   

Abstract

A method for ligating the left anterior descending coronary artery in conscious rats and measuring the resultant cardiovascular responses, arrhythmias, cardiac tissue loss, electrocardiogram (ECG), and mortality is described. Analyses of such responses identified statistically acceptable measures for which precision and interrelationships were defined. Responses to ligation were a variable function of the amount of ligated myocardial tissue. For example, arrhythmia score was a linear function of the square root of the occluded zone size. To test the ability of the model to detect beneficial drugs, verapamil, lidocaine, disopyramide, and quinidine were given. Low doses of verapamil (0.2 mg/kg i.v. + 0.3 mg X kg-1 X h-1), and of disopyramide (10 mg/kg) had few antiarrhythmic, or other actions, whereas high doses of verapamil (20 mg/kg) and disopyramide (40 mg/kg i.v. repeated) were markedly antiarrhythmic as measured by all indices. Quinidine (20 mg/kg i.v. repeated) was also antiarrhythmic but less so than high dose disopyramide and verapamil. Lidocaine (10 mg/kg i.v. + 5 mg X kg-1 X h-1) reduced the incidence of ventricular flutter and fibrillation. High-dose verapamil and quinidine, but not disopyramide, increased the number of nonarrhythmic deaths and the incidence of atrioventricular conduction defects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661688     DOI: 10.1139/y83-193

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  24 in total

1.  Unravelling mechanisms underlying ischaemic arrhythmias - the importance of models.

Authors:  L J Guppy; M J A Walker
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 2.  Principles of safety pharmacology.

Authors:  M K Pugsley; S Authier; M J Curtis
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

3.  Acute hemodynamic effects of coronary artery ligation in conscious rats.

Authors:  R G Schoemaker; J Urquhart; J J Debets; H A Struyker Boudier; J F Smits
Journal:  Basic Res Cardiol       Date:  1990 Jan-Feb       Impact factor: 17.165

4.  Mechanisms underlying the antiarrhythmic properties of beta-adrenoceptor blockade against ischaemia-induced arrhythmias in acutely prepared rats.

Authors:  M J Paletta; S Abraham; G N Beatch; M J Walker
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

5.  Pharmacological blockade of small conductance Ca2+-activated K+ channels by ICA reduces arrhythmic load in rats with acute myocardial infarction.

Authors:  Laura A Hundahl; Stefan M Sattler; Lasse Skibsbye; Jonas G Diness; Jacob Tfelt-Hansen; Thomas Jespersen
Journal:  Pflugers Arch       Date:  2017-03-11       Impact factor: 3.657

6.  The effects of ablations in the central nervous system on arrhythmias induced by coronary occlusion in the rat.

Authors:  M J Curtis; B A Macleod; M J Walker
Journal:  Br J Pharmacol       Date:  1985-11       Impact factor: 8.739

7.  Electrophysiological and antiarrhythmic actions of the kappa agonist PD 129290, and its R,R (+)-enantiomer, PD 129289.

Authors:  M K Pugsley; D A Saint; M P Penz; M J Walker
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

8.  Effects of halothane on arrhythmias induced by myocardial ischaemia.

Authors:  B A MacLeod; R McGroarty; R H Morton; M J Walker
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

9.  Anandamide enhances expression of heat shock protein 72 to protect against ischemia-reperfusion injury in rat heart.

Authors:  Qian Li; Min Shi; Bo Li
Journal:  J Physiol Sci       Date:  2012-09-25       Impact factor: 2.781

10.  Antiarrhythmic actions of verapamil against ischaemic arrhythmias in the rat.

Authors:  M J Curtis; B A MacLeod; M J Walker
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.